Healthcare investment is increasingly intersecting with Portugal’s Golden Visa programme, as digital health and MedTech ventures become the focal point for high‑net‑worth investors seeking both residency benefits and measurable social impact.
The accelerating digital health market
- The global digital‑health market was valued at roughly US$427 billion in 2025 and is projected to grow at a compound annual growth rate (CAGR) above 21 %.
- The AI‑driven healthcare segment is expected to rise from US$15.1 billion in 2022 to over US$187 billion by 2030, implying a ~37 % annual growth rate.
These figures reflect a shift in venture capital toward technology‑enabled care—AI diagnostics, digital therapeutics, and telehealth—viewed as both a growth opportunity and a means to alleviate overstretched public health systems.
Portugal as a hub for health‑tech innovation
Portugal offers a combination of academic talent, relatively low operating costs, and government support that has fostered a nascent health‑tech ecosystem:
- A digital‑therapeutics company founded in 2015 achieved a valuation of about US$4 billion, becoming the country’s first health unicorn. Its AI‑powered physical‑therapy platform serves hundreds of thousands of patients with musculoskeletal conditions, reducing the need for in‑person clinical visits.
- Another firm has built a telehealth suite that enables personalised, digitally orchestrated care journeys, extending quality care to patients regardless of geography or socioeconomic status.
These successes illustrate how Portuguese firms are moving beyond simple digitisation toward reimagining care delivery.
Golden Visa reforms and the shift to investment funds
Portugal’s Golden Visa programme, traditionally linked to real‑estate purchases, has been restructured:
- The property‑investment route has been removed.
- The primary pathway now is the regulated investment‑fund route, requiring a minimum investment of €500,000 in funds overseen by the Portuguese Securities Market Commission (CMVM) that invest mainly in Portuguese companies.
For many investors, the residency advantage is secondary to the impact potential of the underlying investments.
The RYSE Golden Opportunities Fund
- RYSE, a London‑based venture‑capital firm founded in 2017, focuses on HealthTech and MedTech, backing early‑stage and growth‑stage companies that address global healthcare challenges.
- In partnership with Portuguese asset manager Fundbox, RYSE launched the RYSE Golden Opportunities Fund, structured to satisfy the Golden Visa fund‑investment criteria.
- Portfolio companies are evaluated on both commercial prospects and clinical impact at scale, such as reducing hospital readmissions, improving early‑diagnosis rates, expanding specialist‑care access, and lowering systemic costs.
Strategic collaborations bolster the fund’s risk profile:
- Prior partnerships with NHS England on public‑private initiatives aimed at operational efficiency and cost reduction.
- Ongoing relationships with global pharmaceutical players (e.g., Novartis), medical‑device manufacturers (e.g., Medtronic), and insurers across Europe and the United States, providing pathways to market adoption that pure technology funds often lack.
Implications for investors
- Residency: The €500,000 investment grants legal residency in Portugal and a pathway toward EU citizenship.
- Impact: Capital is directed toward companies that aim to relieve pressure on public health systems worldwide.
- Potential returns: Early entry into a rapidly expanding digital‑health market may yield financial upside alongside measurable social outcomes.
Investors prioritising both mobility and tangible health‑system improvements now have a vehicle that aligns personal objectives with broader societal benefits, marking a departure from the historically property‑centric Golden Visa narrative.
Source article: www.imidaily.com
